Once-weekly (70 mg/m2) versus twice weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

被引：0
|
作者：
Moreau, Philippe
Stewart, A. Keith
Dimopoulos, Meletios A.
Siegel, David Samuel DiCapua
Facon, Thierry
Berenson, James R.
Raje, Noopur S.
Berdeja, Jesus G.
Orlowski, Robert Z.
Yang, Hui
Ma, Haijun
Karina Klippel, Zandra
Zahlten-Kumeli, Anita
Mezzi, Khalid
Iskander, Karim
Mateos, Maria-Victoria
机构：
[1] Univ Hosp Nantes, Nantes, France
[2] Mayo Clin, Scottsdale, AZ USA
[3] Univ Athens, Athens, Greece
[4] Hackensack Univ Med Ctr, Hackensack, NJ USA
[5] Reg Univ Hosp Lille, Lille, France
[6] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[7] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Amgen Inc, Thousand Oaks, CA 91320 USA
[11] Univ Salamanca Hosp, IBSAL, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19505
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Kumar, Shaji
    Boccia, Ralph
    Iida, Shinsuke
    Goldschmidt, Hartmut
    Cocks, Kim
    Zahlten-Kumeli, Anita
    Yucel, Emre
    Panjabi, Sumeet
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S240
  • [22] Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study ARROW
    Mateos, Maria-Victoria
    Moreau, Philippe
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEM-KyCyDex)
    Puertas, Borja
    Gonzalez, Veronica
    Sureda, Anna
    Jose Moreno, Ma
    Oriol, Albert
    Esther Gonzalez, Ma
    Rosinol, Laura
    Lopez, Jordi
    Escalante, Fernando
    Martinez Lopez, Joaquin
    Carrillo, Estrella
    Clavero, Esther
    Gonzalez Rodriguez, Ana Pilar
    Dourdil, Victoria
    de Arriba de la Fuente, Felipe
    Sonia Gonzalez, Marta
    Perez de Oteyza, Jaime
    Teodoro Hernandez, Miguel
    Garcia Mateo, Aranzazu
    Blade, Joan
    Lahuerta Palacios, Juan Jose
    San-Miguel, Jesus
    Ocio, Enrique
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S31
  • [24] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
    Moreau, Philippe
    Mateos, Maria-Victoria
    Berenson, James R.
    Weisel, Katja
    Lazzaro, Antonio
    Song, Kevin
    Dimopoulos, Meletios A.
    Huang, Mei
    Zahlten-Kumeli, Anita
    Stewart, A. Keith
    LANCET ONCOLOGY, 2018, 19 (07): : 953 - 964
  • [25] SAFETY OF 150 mg/m2 NAB-PACLITAXEL WEEKLY EITHER AS WEEKLY OR AS 300 mg/m2 BIWEEKLY REGIMEN
    Loibl, S.
    Untch, M.
    Jackisch, C.
    Wiebringhaus, H.
    Forstbauer, H.
    Wachsmann, G.
    Maczynska, Z.
    Nekljudova, V.
    von Minckwitz, G.
    Moebus, V.
    BREAST, 2013, 22 : S101 - S102
  • [26] A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (RJR) Multiple Myeloma
    Badros, Ashraf Z.
    Papadopoulos, Kyriakos P.
    Zojwalla, Naseem
    Lee, Ju RueyJiuan
    Siegel, David S.
    BLOOD, 2012, 120 (21)
  • [27] Real-World Use of Carfilzomib for the Treatment of Relapsed/Refractory Multiple Myeloma in Germany: Once-Weekly and Twice-Weekly Administration Schedules
    Trautmann-Grill, Karolin
    Kossack, Nils
    El Hadad, Laila
    Najafi, Bahar
    Kaehm, Katharina
    Boehm, Doris
    Papkalla, Armin
    Pignot, Marc
    Samuel, Amir
    Katz, Jessica
    Dhamane, Amol D.
    BLOOD, 2024, 144 : 7826 - 7827
  • [28] Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
    Tang, Yong
    Yu, Ye-hua
    Yao, Yi-yun
    Zou, Li-fang
    Dou, Hong-ju
    Wang, Lei
    Zhu, Qi
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 22 - 30
  • [29] Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
    Yong Tang
    Ye-hua Yu
    Yi-yun Yao
    Li-fang Zou
    Hong-ju Dou
    Lei Wang
    Qi Zhu
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 22 - 30
  • [30] Melphalan 200 mg/m2 versus 100 mg/m2 in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Lauta, V. M.
    Montanaro, M.
    Cangialosi, C.
    Morandi, S.
    D'Agostino, F.
    Cavallo, F.
    Omede, P.
    Musto, P.
    Foue, R.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 189 - 189
12345